The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Advances in immunosuppressive therapy have drastically improved acute rejection rates in
kidney transplant recipients over the past five decades. Nevertheless, it should remain high …

Rejection remains the main cause of premature graft loss after kidney transplantation,
despite the use of potent immunosuppression. This highlights the need to better understand …

Advances in maintenance immunosuppression over the past three decades have improved
solid organ transplantation outcomes dramatically. Uninterrupted access to …

Introduction Cytomegalovirus (CMV) remains associated with poor outcomes after kidney
transplantation (kTx). The impact of belatacept on CMV infection remains understudied. In …

Tacrolimus was discovered in 1984 and entered clinical use shortly thereafter, contributing
to successful solid organ transplantation across the globe. In this review, we cover …

Antibodymediated rejection (ABMR) in kidney transplantation is a major cause of late graft
loss, and despite all efforts to date the “standard of care” remains plasmapheresis, IVIg, and …

The past, present, and future of costimulation blockade in o... : Current Opinion in Organ
Transplantation The past, present, and future of costimulation blockade in organ transplantation …

Interrupting T cell costimulatory signals as a strategy to control undesired immune
responses, such as occur in autoimmunity or transplantation, has the potential to alleviate …

While most human T cells express the CD28 costimulatory molecule constitutively, it is well
known that age, inflammation, and viral infection can drive the generation of CD28 null T …